OCP Announces Date of Second Quarter and First Half 2024 Earnings
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2024 results on Tuesday, September 24, 2024. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 2:00 p.m. Morocco and London time (GMT+1).
OCP senior management will host a conference call to discuss second quarter and first half 2024 results at 10:00 a.m. EDT, 3:00 p.m. Morocco and London time (GMT+1) on Tuesday, September 24, 2024, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers.
Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma.
About OCP
OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive access to the largest phosphate rock reserve base in the world. It is one of the lowest cost producers of phosphate rock in the industry and has become a leading player in production and trade volumes across the phosphate value chain. OCP employs 21,000 people and contributes to regional development through its mining and fertilizer operations, and through its sustainability program.
For more information visit: www.ocpgroup.ma.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917141125/en/
Contacts
OCP - Investor Relations
Ghita Laraki, +212 522 924 183
g.laraki@ocpgroup.ma
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest Integrates with Assembla to Streamline Bug Tracking for Development Teams3.6.2025 18:00:00 EEST | Press release
LambdaTest, a unified agentic AI and cloud engineering platform, has announced its partnership with Assembla, a robust cloud-based platform for version control and project management. This collaboration enables software development teams to streamline their bug tracking processes and improve overall productivity. LambdaTest offers developers an exhaustive list of cloud-based testing solutions, including cross-browser compatibility testing, Web and App automation testing, and Real Device testing. Assembla users can now easily integrate with the LambdaTest platform to seamlessly mark bugs with detailed screenshots and assign them to team members. "This integration between LambdaTest and Assembla allows development teams to optimize their testing and bug tracking processes," said Mayank Bhola, Co-Founder and Head of Product at LambdaTest. "By connecting these platforms, teams can maintain uninterrupted workflow while ensuring thorough documentation and tracking of issues discovered during
The Future of AI in the AEC Industry Unveiled at BST Global’s 2025 AI Summit3.6.2025 17:41:00 EEST | Press release
BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, hosted its second annual AI Summit, May 6–8, 2025, in Palm Beach, FL. The premier event brought together 12 thought leaders from some of the world’s most influential firms, including Arcadis, Arup, AtkinsRéalis, Gensler, GHD, Jacobs, Mott MacDonald, NVIDIA, Parsons, Stantec, and WSP to share insights on how AI is reshaping the future of the AEC industry. Attendees as well as the broader AEC community praised the 2025 AI Summit for its timely content and line-up of industry trailblazers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603538561/en/ BST Global Chief Executive Officer Javier A. Baldor officially kicks off the AI Summit’s first full day of sessions by presenting his perspective on the driving forces impacting the AEC industry and the world at large. He shares three key ways AI and big data will transform nearly
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 20253.6.2025 17:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 2025 EHA Congress, including late-breaking data for our first in class, mutCALR-directed monoclonal antibody, INCA033989,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We believe the data that will be presented at the late-breaking session demonstrate the impact of the novel mechanism of action of this monoclonal antibody against mutCALR-driven essential thrombocythemia (ET), and support its potential to be a disease modifying agent and thus transform the treatment of patients with myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET)." Key Incyte abstracts accepted for presentation at EHA include: Late-Breaking Or
European Commission Approves ADCETRIS ® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD3.6.2025 17:12:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma is based on the results of the randomized Phase 3 HD21 trial. The study met its co-primary safety and efficacy endpoints, with BrECADD demonstrating significantly superior safety as assessed by treatment-related morbidity (TRMB) and non-inferior progression-free survival (PFS) in comparison to escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP), a standard of ca
Automotive Industry Shifts Gears As Talent and Technology Take Center Stage3.6.2025 17:00:00 EEST | Press release
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the results of the 10th annual “State of Smart Manufacturing Report: Automotive Edition.” The global study encompasses the responses of 130 leaders across automotive and tire manufacturers, original equipment manufacturers, engineering procurement companies and systems integrators across 15 countries, revealing a sector rapidly embracing change to stay competitive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603797393/en/ Rockwell Automation report shows manufacturers are leaning into AI, upskilling and innovation to overcome workforce and operational challenges. Workforce pressures have emerged as the most urgent challenge for automotive companies, signaling a significant shift from last year’s findings. At the same time, concerns around cybersecurity have declined, suggesti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom